Dhanji Rajani | Immunology and Microbiology | Best Researcher Award

Dr. Dhanji Rajani | Immunology and Microbiology | Best Researcher Award

Microbiologist at Microcare laboratory and Tuberculosis research centre, India

Dr. Dhanji Popatbhai Rajani is a distinguished microbiologist with nearly two decades of experience in medical microbiology and diagnostics. He has made significant contributions to tuberculosis (TB) research, including evaluating innovative PCR tests for MDR TB and developing non-invasive, low-cost rapid diagnostics under prestigious government-funded projects like IMPRINT. With over 106 research publications and 24 patents, his work spans green synthesis, drug discovery, and sustainable methodologies. Dr. Rajani has received accolades such as the Best Performance Award for TB diagnosis from Surat Municipal Corporation in 2015 and 2016, highlighting his impact on public health. Currently leading diagnostics at Microcare Lab & TRC, he combines clinical expertise with research innovation. His leadership roles and commitment to advancing microbiology through cutting-edge research, sustainable practices, and impactful diagnostics establish him as a leading figure in his field, making him an exceptional candidate for recognition like the Best Researcher Award.

Professional Profile 

Education

Dr. Dhanji Popatbhai Rajani has a solid academic foundation in microbiology and medical diagnostics. He earned his Bachelor of Science (B.Sc) in Microbiology from the Sir P. P. Institute of Science in 2000, followed by a Postgraduate Diploma in Medical Laboratory Technology (PGDMLT) from K. K. Jani Paramedical Institute in 2001, which honed his technical expertise in laboratory sciences. Dr. Rajani further advanced his academic qualifications with a Master of Science (M.Sc) in Medical Microbiology from the Aditya Vikram Birla Post Graduate Institute in 2003, focusing on clinical and diagnostic microbiology. His academic journey culminated in a Ph.D. in Medical Microbiology from Bhavnagar University in 2012, where he specialized in advanced research methodologies and innovative diagnostics. This comprehensive education has laid the groundwork for his impactful career in microbiology, driving significant advancements in diagnostic research, particularly in tuberculosis and sustainable medical innovations.

Professional Experience

Dr. Dhanji Popatbhai Rajani has an extensive professional career in microbiology, marked by leadership roles and impactful contributions to clinical diagnostics. Since 2004, he has served as a Microbiologist at Microcare Lab & TRC, where he has led diagnostic and research initiatives, particularly in tuberculosis (TB) and other infectious diseases. From 2009 to 2013, he was the Chief Microbiologist at Smt. R. B. Shah Mahavir Hospital, where he spearheaded clinical diagnostic services and strengthened laboratory operations. With nearly two decades of experience, Dr. Rajani has established himself as a leader in medical microbiology, combining hands-on diagnostic expertise with cutting-edge research. His work has not only advanced TB diagnostics but also contributed to sustainable and innovative practices in microbiology. Dr. Rajani’s professional journey reflects a blend of clinical excellence, research innovation, and leadership, making him a pivotal figure in his field.

Research Interest

Dr. Dhanji Popatbhai Rajani’s research interests lie at the intersection of medical microbiology, innovative diagnostics, and sustainable scientific methodologies. He is deeply committed to advancing tuberculosis (TB) diagnostics, focusing on developing non-invasive, cost-effective, and rapid diagnostic tools that address global health challenges. His work also includes exploring green synthesis methods, such as using natural catalysts, to create sustainable and environmentally friendly processes in drug development. Dr. Rajani’s research encompasses the design and biological evaluation of novel compounds with antifungal, antimalarial, and antitubercular properties, integrating advanced techniques like molecular docking, ADME-Tox analysis, and pharmacophore modeling. With a keen interest in sustainable innovations, he has also contributed to the synthesis of bioactive compounds using eco-friendly methods. Dr. Rajani’s multidisciplinary approach reflects his commitment to improving public health through groundbreaking research and sustainable solutions, positioning him as a leader in medical microbiology and diagnostics.

Award and Honor

Dr. Dhanji Popatbhai Rajani has been recognized for his outstanding contributions to medical microbiology and diagnostics through several prestigious awards and honors. He received the Best Performance Award for TB diagnosis from the Surat Municipal Corporation in both 2015 and 2016, acknowledging his excellence in advancing tuberculosis diagnostics and public health impact. These accolades highlight his dedication to combating TB through innovative diagnostic solutions and his commitment to improving healthcare outcomes. Dr. Rajani’s work has garnered widespread appreciation for its relevance and effectiveness in addressing critical challenges in infectious disease management. These honors underscore his ability to translate research into practical applications, benefiting communities and setting new standards in diagnostic microbiology. With his achievements and consistent recognition, Dr. Rajani has established himself as a leading figure in his field, making significant strides in medical innovation and public health.

Conclusion

Dr. Dhanji Popatbhai Rajani is a strong candidate for the Best Researcher Award due to his extensive contributions to medical microbiology, particularly in TB diagnostics and drug synthesis. His robust portfolio of research papers, patents, and awards, combined with leadership in impactful projects, underscores his eligibility. Strengthening international collaboration and diversifying research impact would further elevate his profile for future recognition.

Publications Top Noted

  • Title: Synthesis of benzimidazolyl-1, 3, 4-oxadiazol-2ylthio-N-phenyl (benzothiazolyl) acetamides as antibacterial, antifungal and antituberculosis agents
    Authors: RV Patel, PK Patel, P Kumari, DP Rajani, KH Chikhalia
    Year: 2012
    Citation: 191
  • Title: Synthesis and identification of β-aryloxyquinolines and their pyrano [3, 2-c] chromene derivatives as a new class of antimicrobial and antituberculosis agents
    Authors: DC Mungra, MP Patel, DP Rajani, RG Patel
    Year: 2011
    Citation: 161
  • Title: A strategic approach to the synthesis of functionalized spirooxindole pyrrolidine derivatives: in vitro antibacterial, antifungal, antimalarial and antitubercular studies
    Authors: S Haddad, S Boudriga, TN Akhaja, JP Raval, F Porzio, A Soldera, M Askri, DP Rajani
    Year: 2015
    Citation: 112
  • Title: Synthesis and studies of novel 2-(4-cyano-3-trifluoromethylphenyl amino)-4-(quinoline-4-yloxy)-6-(piperazinyl/piperidinyl)-s-triazines as potential antimicrobial agents
    Authors: RV Patel, P Kumari, DP Rajani, KH Chikhalia
    Year: 2011
    Citation: 109
  • Title: Synthesis of coumarin-based 1,3,4-oxadiazol-2ylthio-N-phenyl/benzothiazolyl acetamides as antimicrobial and antituberculosis agents
    Authors: RV Patel, P Kumari, DP Rajani, KH Chikhalia
    Year: 2013
    Citation: 105
  • Title: Antimicrobial, Anti-TB, Anticancer and Anti-HIV Evaluation of New s-Triazine-Based Heterocycles
    Authors: RV Patel, P Kumari, DP Rajani, C Pannecouque, E De Clercq, KH Chikhalia
    Year: 2012
    Citation: 79
  • Title: New 2-benzylsulfanyl-nicotinic acid based 1, 3, 4-oxadiazoles: Their synthesis and biological evaluation
    Authors: NB Patel, AC Purohit, DP Rajani, R Moo-Puc, G Rivera
    Year: 2013
    Citation: 76
  • Title: Hydroxyl alkyl ammonium ionic liquid assisted green and one-pot regioselective access to functionalized pyrazolodihydropyridine core and their pharmacological evaluation
    Authors: DM Patel, MG Sharma, RM Vala, I Lagunes, A Puerta, JM Padrón, DP Rajani
    Year: 2019
    Citation: 72
  • Title: Synthesis, characterization and pharmacological activities of 2-[4-cyano-(3-trifluoromethyl) phenyl amino)]-4-(4-quinoline/coumarin-4-yloxy)-6-(fluoropiperazinyl)-s-triazines
    Authors: RV Patel, P Kumari, DP Rajani, KH Chikhalia
    Year: 2011
    Citation: 68
  • Title: A Practical Green Visit to the Functionalized [1,2,4]Triazolo[5,1‐b]quinazolin‐8(4H)one Scaffolds Using the Group‐Assisted Purification (GAP) Chemistry and Their Biological Evaluation
    Authors: DM Patel, RM Vala, MG Sharma, DP Rajani, HM Patel
    Year: 2019
    Citation: 65
  • Title: Synthesis and evaluation of new chalcones, derived pyrazoline and cyclohexenone derivatives as potent antimicrobial, antitubercular and antileishmanial agents
    Authors: V Monga, K Goyal, M Steindel, M Malhotra, DP Rajani, SD Rajani
    Year: 2014
    Citation: 64
  • Title: Green approach for synthesis of bioactive Hantzsch 1, 4-dihydropyridine derivatives based on thiophene moiety via multicomponent reaction
    Authors: MG Sharma, DP Rajani, HM Patel
    Year: 2017
    Citation: 57

 

Jean-nicolas boursiquot | Immunology | Best Researcher Award

🌟Dr. Jean-nicolas boursiquot, Immunology, Best Researcher Award 🏆

  •  Doctorate at CHU de Quebec, Canada
 

Jean-Nicolas Boursiquot is a highly qualified medical professional specializing in allergy and clinical immunology. With a comprehensive educational background and extensive research experience, Boursiquot has made significant contributions to the field through publications, presentations, and teaching activities. His dedication to advancing medical knowledge and patient care is evident in his multifaceted professional journey, marked by numerous affiliations, academic commitments, and media engagements. Boursiquot’s expertise encompasses a wide range of topics within allergy and immunology, making him a respected figure in both academic and clinical settings.

Author Metrics:

Scopus Profile

Boursiquot’s author metrics reflect a prolific and impactful academic career, with a substantial number of publications in peer-reviewed journals, presentations at scientific conferences, and media engagements.

  • Citations: 385 citations by 385 documents
  • Documents: 9
  • h-index: 5

Education:

  • Ph.D. in Medicine (M.D.), Laval University, Quebec, Canada, 1999-2004
  • Intensive ESL (English as Second Language) Training, University of Manitoba, Winnipeg, Canada, 1999
  • International Baccalaureate (Pure Sciences), Small Seminary of Quebec, Quebec, Canada, 1997-1999

Research Focus:

Boursiquot’s research focuses primarily on allergy and clinical immunology, with particular interests in immunodeficiencies, allergic rhinitis, asthma, drug allergies, and angioedema. He has conducted studies on various aspects of these conditions, contributing to advancements in diagnosis, treatment, and understanding of underlying mechanisms.

Professional Journey:

Boursiquot’s professional journey spans diverse roles in academia, clinical practice, research, and education:

  • Clinical Allergist and Immunologist at CSSS DES ILES and CSSS DE LAC-SAINT-JEAN-EST
  • Clinical Professor and Educational Ambassador at Laval University
  • Member of various professional committees and boards, including the Canadian Society of Allergy and Clinical Immunology (CSACI) and the Association of Allergists and Immunologists of Quebec (AAIQ)
  • Active involvement in medical education and training, including teaching medical students, residents, and clinicians

Honors & Awards:

  • Recipient of the CMDP of CHUQ and CHUQ-CMDP Foundation Award in 2010
  • Awarded the Humanism Prize in 1997 by the Small Seminary of Quebec

Research Timeline:

1999-2004: Pursued Ph.D. in Medicine at Laval University, Quebec, Canada

2007-2009: Completed Residency in Allergy and Clinical Immunology at McGill University, Montreal, Canada

2010: Conducted Research Fellowship at Pr Éric Oksenhendler Service, St-Louis Hospital, Paris, France

2013-present: Actively engaged in clinical practice, research, teaching, and professional development, making significant contributions to the field of allergy and clinical immunology.

Publications Noted & Contributions:

Boursiquot has made significant contributions to the medical literature through published articles, scientific posters, and presentations at conferences. His research has been focused on topics such as immunodeficiencies, allergic reactions, and treatment strategies. He has also engaged with the media to raise awareness and educate the public about allergies and related conditions.

Safety of Direct Drug Provocation for the Evaluation of Penicillin Allergy in Low-Risk Adults

  • Authors: Brillant-Marquis, F., Proulx, É., Ratnarajah, K., De Serres, G., Drolet, J.-P., Boursiquot, J.-N.
  • Journal: Journal of Allergy and Clinical Immunology: In Practice, 2024, 12(2), pp. 451–457.e2
  • Abstract: [Not available]
  • Citations: 1
  • Note: Open access

A Patient Charter for Chronic Urticaria

  • Authors: Maurer, M., Albuquerque, M., Boursiquot, J.-N., Nigen, S., Winders, T.
  • Journal: Advances in Therapy, 2024, 41(1), pp. 14–33
  • Abstract: [Not available]
  • Citations: 0
  • Review: Open access

Bradykinin-induced angioedema in the emergency department

  • Authors: Hébert, J., Boursiquot, J.-N., Chapdelaine, H., Lepeshkina, O., Vincent, M.
  • Journal: International Journal of Emergency Medicine, 2022, 15(1), 15
  • Abstract: [Not available]
  • Citations: 2
  • Erratum: Open access

Erratum: The International/Canadian Hereditary Angioedema Guideline

  • Authors: Betschel, S., Badiou, J., Binkley, K., Stark, D., Tsai, E.
  • Journal: Allergy, Asthma and Clinical Immunology, 2020, 16(1), 16
  • Abstract: [Not available]
  • Citations: 1
  • Erratum: Open access

Patient and physician perceptions of seasonal allergic rhinitis and allergen immunotherapy: A parallel physician-patient survey

  • Authors: Ellis, A.K., Boursiquot, J., Carr, S., Graham, F., Masse, M.-S.
  • Journal: Allergy, Asthma and Clinical Immunology, 2020, 16(1), 15
  • Abstract: [Not available]
  • Citations: 8